Clinical Trials Logo

Clinical Trial Summary

This is a single-centre open label phase II study evaluating the effect of lenvatinib treatment for restoring radioiodine uptake and retention in radioiodine-refractory (RAI-R) thyroid cancer to warrant I-131 therapy.


Clinical Trial Description

RAI-R DTC patients starting standard-of-care lenvatinib treatment will be included in this study. Prior to lenvatinib treatment, patients will undergo I-124 PET/CT to quantify RAI uptake and retention at baseline. The first half of the intended sample size (cohort 1) will be treated with lenvatinib for a total of 12 weeks. After 6- and 12-week treatment, patients will undergo I-124 PET/CT dosimetry to evaluate the redifferentiation effect, assess expected absorbed lesion doses and maximum tolerable activity. Results between 6- and 12-week lenvatinib treatment will be compared to select the lenvatinib treatment duration that leads to highest extent of redifferentiation. The next patients (cohort 2) will then receive lenvatinib for either 6 or 12 weeks. Patients will undergo subsequent I-131 therapy if a clinically meaningful lesion dose is expected and toxicity is deemed acceptable. For all patients eligible for I-131 therapy, lenvatinib is discontinued prior to administration of I-131 and intra-therapeutic I-131 SPECT dosimetry will be performed for dose verification. Patients who are not eligible for I-131 therapy, will continue lenvatinib treatment at the discretion of the treating physician. Biopsies are performed at baseline and after 6-week lenvatinib treatment to evaluate alterations at the transcriptional and translational level in biopted tumor lesions. Patients will be followed up according to current guidelines for a total of 9 months after initiating lenvatinib treatment. Metabolic and biochemical response will be assessed using F-18 FDG PET/CT and Tg levels, respectively. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04858867
Study type Interventional
Source Leiden University Medical Center
Contact Maaike Dotinga, MSc
Phone +31715263695
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date May 1, 2021
Completion date January 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02870569 - Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer Phase 2
Active, not recruiting NCT01876784 - Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Phase 3
Recruiting NCT03690388 - A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Phase 3
Recruiting NCT02638077 - Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China N/A
Recruiting NCT01700699 - Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT04563780 - The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
Completed NCT03191643 - PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer N/A
Completed NCT02278198 - Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123 Phase 1
Active, not recruiting NCT01263951 - Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone Phase 2
Completed NCT00295763 - A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Phase 3
Recruiting NCT04391244 - Investigating National Solutions for Personalised Iodine-131 Radiation Exposure
Recruiting NCT04137185 - Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients Phase 1/Phase 2
Active, not recruiting NCT02586337 - Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) Phase 2/Phase 3
Not yet recruiting NCT03416686 - Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy N/A
Completed NCT02304757 - 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Decreased Bone Mineral Density N/A
Recruiting NCT03986437 - A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.
Enrolling by invitation NCT03794375 - Primary Care Transfer for Thyroid Cancer Patients N/A
Recruiting NCT04857086 - The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China